GEMCITABINE AND CISPLATIN COMBINED WITH REGIONAL HYPERTHERMIA AS SECOND-LINE TREATMENT IN PATIENTS WITH GEMCITABINE-REFRACTORY ADVANCED PANCREATIC CANCER

被引：0
|
作者：
Lechner, Katharina [1 ]
Berger, Frank [2 ]
Dieterle, Nelli [1 ]
Abdel-Rahman, Sultan [1 ]
Salat, Christoph
Issels, Rolf [3 ]
机构：
[1] Univ Munich, Klinikum Grosshadern, Med Ctr, Dept Internal Med 3, D-8000 Munich, Germany
[2] Univ Munich, Inst Clin Radiol, Munich, Germany
[3] Helmholtz Zentrum Munich, Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [1] Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
    Tschoep-Lechner, Katharina Elisabeth
    Milani, Valeria
    Berger, Frank
    Dieterle, Nelli
    Abdel-Rahman, Sultan
    Salat, Christoph
    Issels, Rolf-Dieter
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2013, 29 (01) : 8 - 16
  • [2] Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
    Park, Se Jun
    Kim, Hyunho
    Shin, Kabsoo
    Lee, Myung Ah
    Hong, Tae Ho
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 11 (11) : 1021 - 1030
  • [3] Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
    Se Jun Park
    Hyunho Kim
    Kabsoo Shin
    Myung Ah Lee
    Tae Ho Hong
    World Journal of Gastrointestinal Oncology, 2019, (11) : 1021 - 1030
  • [4] Second-Line Therapy for Gemcitabine-Refractory Pancreatic Cancer : Is There a Standard?
    Almhanna, Khaldoun
    Kim, Richard
    ONCOLOGY-NEW YORK, 2008, 22 (10): : 1176 - 1183
  • [5] Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study
    Maeda, Shimpei
    Motoi, Fuyuhiko
    Onogawa, Tohru
    Morikawa, Takanori
    Shigeru, Ottomo
    Sakata, Naoaki
    Takadate, Tatsuyuki
    Naitoh, Takeshi
    Rikiyama, Toshiki
    Katayose, Yu
    Egawa, Shinichi
    Unno, Michiaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2011, 16 (05) : 539 - 545
  • [6] Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study
    Shimpei Maeda
    Fuyuhiko Motoi
    Tohru Onogawa
    Takanori Morikawa
    Ottomo Shigeru
    Naoaki Sakata
    Tatsuyuki Takadate
    Takeshi Naitoh
    Toshiki Rikiyama
    Yu Katayose
    Shinichi Egawa
    Michiaki Unno
    International Journal of Clinical Oncology, 2011, 16
  • [7] Oral chemotherapy as second-line treatment option for gemcitabine-refractory advanced pancreatic cancer with poor performance status.
    Park, Se Jun
    Lee, Myung Ah
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [8] Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer
    Lee, Jeung Eun
    Lee, Hee Seung
    Chung, Moon Jae
    Park, Jeong Youp
    Park, Seung Woo
    Song, Si Young
    Bang, Seungmin
    GUT AND LIVER, 2020, 14 (01) : 135 - 143
  • [9] Capecitabine is an effective treatment in gemcitabine-refractory advanced pancreatic cancer
    Arrazubi, V
    Illarramendi, J.
    Lainez, N.
    Salgado, E.
    Martinez, M.
    Amillano, K.
    Vera, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 75 - 75
  • [10] Second-Line Therapy for Gemcitabine-Refractory Pancreatic Cancer: Is There a Standard? The Almhanna/Kim Article Reviewed
    Ko, Andrew H.
    ONCOLOGY-NEW YORK, 2008, 22 (10): : 1190 - +
12345